Urinary F2-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes

@inproceedings{Ilyasova2012UrinaryFA,
  title={Urinary F2-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes},
  author={Dora Il'yasova and Ivan Spasojevi{\'c} and Karel Base and Haoyue H Zhang and Frances M Wang and Sarah P. Young and David S. Millington and Ralph B. D’Agostino and Lynne E. Wagenknecht},
  booktitle={Diabetes care},
  year={2012}
}
OBJECTIVE We have previously reported evidence of an inverse association between a urinary F(2)-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRAS cohort. RESEARCH DESIGN AND METHODS This prospective study included 138 incident type 2 diabetes case and 714 noncase subjects. Four F(2)-isoprostanes (iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS